These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 18258606

  • 1. Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells.
    Kim KK, Lee JJ, Yang Y, You KH, Lee JH.
    Carcinogenesis; 2008 Apr; 29(4):704-12. PubMed ID: 18258606
    [Abstract] [Full Text] [Related]

  • 2. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
    Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM, Song KS, Lee YH, Kim YJ, Lee JJ, Choi I, Lee JH.
    Cancer Res; 2003 Aug 01; 63(15):4648-55. PubMed ID: 12907645
    [Abstract] [Full Text] [Related]

  • 3. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
    Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D.
    Cancer Res; 2006 Feb 15; 66(4):2028-37. PubMed ID: 16489002
    [Abstract] [Full Text] [Related]

  • 4. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
    Wang S, Huang X, Lee CK, Liu B.
    Oncogene; 2010 Jul 22; 29(29):4225-36. PubMed ID: 20498641
    [Abstract] [Full Text] [Related]

  • 5. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
    Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D.
    Clin Cancer Res; 2004 Oct 15; 10(20):6779-88. PubMed ID: 15501954
    [Abstract] [Full Text] [Related]

  • 6. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.
    Mol Cancer Res; 2007 Apr 15; 5(4):393-401. PubMed ID: 17426253
    [Abstract] [Full Text] [Related]

  • 7. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
    Niu G, Carter WB.
    Cancer Res; 2007 Feb 15; 67(4):1487-93. PubMed ID: 17308086
    [Abstract] [Full Text] [Related]

  • 8. Silibinin inhibits hypoxia-inducible factor-1alpha and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy.
    García-Maceira P, Mateo J.
    Oncogene; 2009 Jan 22; 28(3):313-24. PubMed ID: 18978810
    [Abstract] [Full Text] [Related]

  • 9. A hypoxia-independent up-regulation of hypoxia-inducible factor-1 by AKT contributes to angiogenesis in human gastric cancer.
    Lee BL, Kim WH, Jung J, Cho SJ, Park JW, Kim J, Chung HY, Chang MS, Nam SY.
    Carcinogenesis; 2008 Jan 22; 29(1):44-51. PubMed ID: 17984117
    [Abstract] [Full Text] [Related]

  • 10. The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells.
    Wollmann W, Goodman ML, Bhat-Nakshatri P, Kishimoto H, Goulet RJ, Mehrotra S, Morimiya A, Badve S, Nakshatri H.
    Carcinogenesis; 2005 May 22; 26(5):900-7. PubMed ID: 15677629
    [Abstract] [Full Text] [Related]

  • 11. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
    Kunz C, Borghouts C, Buerger C, Groner B.
    Mol Cancer Res; 2006 Dec 22; 4(12):983-98. PubMed ID: 17189388
    [Abstract] [Full Text] [Related]

  • 12. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
    Manuvakhova M, Thottassery JV, Hays S, Qu Z, Rentz SS, Westbrook L, Kern FG.
    Oncogene; 2006 Sep 28; 25(44):6003-14. PubMed ID: 16682955
    [Abstract] [Full Text] [Related]

  • 13. Heregulinbeta activates store-operated Ca2+ channels through c-erbB2 receptor level-dependent pathway in human breast cancer cells.
    Liao JY, Li LL, Wei Q, Yue JC.
    Arch Biochem Biophys; 2007 Feb 15; 458(2):244-52. PubMed ID: 17214955
    [Abstract] [Full Text] [Related]

  • 14. Macrophage inhibitory cytokine-1 transactivates ErbB family receptors via the activation of Src in SK-BR-3 human breast cancer cells.
    Park YJ, Lee H, Lee JH.
    BMB Rep; 2010 Feb 15; 43(2):91-6. PubMed ID: 20193126
    [Abstract] [Full Text] [Related]

  • 15. HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression.
    Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B.
    Cancer Res; 2009 Nov 01; 69(21):8403-11. PubMed ID: 19826038
    [Abstract] [Full Text] [Related]

  • 16. Metastatic potential of 21T human breast cancer cells depends on Akt/protein kinase B activation.
    Qiao M, Iglehart JD, Pardee AB.
    Cancer Res; 2007 Jun 01; 67(11):5293-9. PubMed ID: 17545609
    [Abstract] [Full Text] [Related]

  • 17. Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway.
    Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G.
    Cancer Res; 2007 Jan 01; 67(1):289-99. PubMed ID: 17210710
    [Abstract] [Full Text] [Related]

  • 18. Overexpression of ErbB2 enhances ethanol-stimulated intracellular signaling and invasion of human mammary epithelial and breast cancer cells in vitro.
    Ma C, Lin H, Leonard SS, Shi X, Ye J, Luo J.
    Oncogene; 2003 Aug 14; 22(34):5281-90. PubMed ID: 12917629
    [Abstract] [Full Text] [Related]

  • 19. p38MAPK-activated AKT in HER-2 overexpressing human breast cancer cells acts as an EGF-independent survival signal.
    Diehl KM, Grewal N, Ethier SP, Woods-Ignatoski KM.
    J Surg Res; 2007 Sep 14; 142(1):162-9. PubMed ID: 17612563
    [Abstract] [Full Text] [Related]

  • 20. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
    Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC.
    Clin Cancer Res; 1997 Sep 14; 3(9):1629-34. PubMed ID: 9815853
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.